Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 09:54:16 AM Tue, 14 Apr 2020   Contact Information Yiling Lu Associated Profiles  Professor, Genomic Medicine, UT MD Anderson Cancer Center, Director, CCSG Shared Resource Functional Proteomics RPPA Core   2SCR3.3022, Room No.: Unit 0950    yilinglu@mdanderson.org     (713) 563-4218    Web Link    Neoplasms, Phosphatidylinositol 3-Kinase, Protein Array Analysis, Mutation, Breast Neoplasms, Ovarian Neoplasms, Proteomics, Atlases    Associated Profiles Research and Expertise Affiliations Appointments  Research and Expertise Research Interests   My research focuses on identifying and characterizing novel cellular targets for cancer therapy by Systems Biology approach. Cancer systems biology demonstrates that multiple genomic aberrations in cancer cells integrate at the protein level to alter cellular functions. For the past years, I have spent my major efforts to develop and validate the technology of Reverse Phase Protein Arrays (RPPA) in its application of cancer systems biology. RPPA provides robust information to integrate the consequence of genetic aberrations in cancer, to validate therapeutic targets, to demonstrate on- and off-target activity of drugs and to evaluate drug pharmacodynamics. It also characterizes, across large numbers of samples or cell lines, the basal protein expression levels, growth factor- or ligand-induced effects and time resolved responses appropriate for systems biology analysis. To better understand cancer pathobiology, we have joined TCGA program and characterized signaling networks in 3649 cancer samples across different diseases. In addition, we have completed screenings by RPPA with (a) 779 siRNAs targeting protein and lipid kinases; (b) 879 human genome miRNAs; and (c) multiple drug libraries in breast and ovarian cancer cells aiming to identify novel cellular targets for cancer therapy. The studies builds up a "fingerprint" of activity from chemical and genetic manipulations that can rapidly identify novel therapeutic targets as well as determine actions of unknown molecules. As a CCSG RPPA Core director, I have demonstrated myself as a leadership in the field to provide M. D. Anderson investigators and the larger research community around the world with our expertise on functional proteomics studies. Further, I have extensive experiences in collaboration with investigators nationwide and we have successfully completed multiple projects, especially on the studies targeting PI3K-AKT pathway in breast and ovarian cancers. In summary, I have prepared myself as a successful and productive cancer researcher with major contribution to the field of targeted cancer therapy by proteomics approach. My expertise and experiences will lead to the completion of the proposed project.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia John S. Dunn GCC for Chemical Genomics  Appointments Title Department / School Institution Professor Genomic Medicine UT MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.